The global Flu Vaccination market size was valued at US$ 9109 million in 2024 and is forecast to a readjusted size of USD 12920 million by 2031 with a CAGR of 5.2% during review period.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Flu Vaccination market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Flu Vaccination market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Flu Vaccination market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Flu Vaccination market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Flu Vaccination market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Flu Vaccination
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Flu Vaccination market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Flu Vaccination market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
麻豆原创 segment by Application
6 Months to 3 Years
Above 3 Years
Major players covered
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Flu Vaccination product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Flu Vaccination, with price, sales quantity, revenue, and global market share of Flu Vaccination from 2020 to 2025.
Chapter 3, the Flu Vaccination competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Flu Vaccination breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Flu Vaccination market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Flu Vaccination.
Chapter 14 and 15, to describe Flu Vaccination sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Flu Vaccination Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Trivalent Influenza Vaccine
1.3.3 Quadrivalent Influenza Vaccine
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Flu Vaccination Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 6 Months to 3 Years
1.4.3 Above 3 Years
1.5 Global Flu Vaccination 麻豆原创 Size & Forecast
1.5.1 Global Flu Vaccination Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Flu Vaccination Sales Quantity (2020-2031)
1.5.3 Global Flu Vaccination Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Flu Vaccination Product and Services
2.1.4 Sanofi Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Sanofi Recent Developments/Updates
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Flu Vaccination Product and Services
2.2.4 CSL Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 CSL Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Flu Vaccination Product and Services
2.3.4 GSK Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 GSK Recent Developments/Updates
2.4 Viatris
2.4.1 Viatris Details
2.4.2 Viatris Major Business
2.4.3 Viatris Flu Vaccination Product and Services
2.4.4 Viatris Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Viatris Recent Developments/Updates
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Flu Vaccination Product and Services
2.5.4 AstraZeneca Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 AstraZeneca Recent Developments/Updates
2.6 Hualan Bio
2.6.1 Hualan Bio Details
2.6.2 Hualan Bio Major Business
2.6.3 Hualan Bio Flu Vaccination Product and Services
2.6.4 Hualan Bio Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Hualan Bio Recent Developments/Updates
2.7 Changchun Institute of Biological
2.7.1 Changchun Institute of Biological Details
2.7.2 Changchun Institute of Biological Major Business
2.7.3 Changchun Institute of Biological Flu Vaccination Product and Services
2.7.4 Changchun Institute of Biological Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Changchun Institute of Biological Recent Developments/Updates
2.8 Sinovac
2.8.1 Sinovac Details
2.8.2 Sinovac Major Business
2.8.3 Sinovac Flu Vaccination Product and Services
2.8.4 Sinovac Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Sinovac Recent Developments/Updates
2.9 BCHT
2.9.1 BCHT Details
2.9.2 BCHT Major Business
2.9.3 BCHT Flu Vaccination Product and Services
2.9.4 BCHT Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 BCHT Recent Developments/Updates
2.10 Jiangsu GDK
2.10.1 Jiangsu GDK Details
2.10.2 Jiangsu GDK Major Business
2.10.3 Jiangsu GDK Flu Vaccination Product and Services
2.10.4 Jiangsu GDK Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Jiangsu GDK Recent Developments/Updates
2.11 KM Biologics
2.11.1 KM Biologics Details
2.11.2 KM Biologics Major Business
2.11.3 KM Biologics Flu Vaccination Product and Services
2.11.4 KM Biologics Flu Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 KM Biologics Recent Developments/Updates
3 Competitive Environment: Flu Vaccination by Manufacturer
3.1 Global Flu Vaccination Sales Quantity by Manufacturer (2020-2025)
3.2 Global Flu Vaccination Revenue by Manufacturer (2020-2025)
3.3 Global Flu Vaccination Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Flu Vaccination by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Flu Vaccination Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Flu Vaccination Manufacturer 麻豆原创 Share in 2024
3.5 Flu Vaccination 麻豆原创: Overall Company Footprint Analysis
3.5.1 Flu Vaccination 麻豆原创: Region Footprint
3.5.2 Flu Vaccination 麻豆原创: Company Product Type Footprint
3.5.3 Flu Vaccination 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Flu Vaccination 麻豆原创 Size by Region
4.1.1 Global Flu Vaccination Sales Quantity by Region (2020-2031)
4.1.2 Global Flu Vaccination Consumption Value by Region (2020-2031)
4.1.3 Global Flu Vaccination Average Price by Region (2020-2031)
4.2 North America Flu Vaccination Consumption Value (2020-2031)
4.3 Europe Flu Vaccination Consumption Value (2020-2031)
4.4 Asia-Pacific Flu Vaccination Consumption Value (2020-2031)
4.5 South America Flu Vaccination Consumption Value (2020-2031)
4.6 Middle East & Africa Flu Vaccination Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Flu Vaccination Sales Quantity by Type (2020-2031)
5.2 Global Flu Vaccination Consumption Value by Type (2020-2031)
5.3 Global Flu Vaccination Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Flu Vaccination Sales Quantity by Application (2020-2031)
6.2 Global Flu Vaccination Consumption Value by Application (2020-2031)
6.3 Global Flu Vaccination Average Price by Application (2020-2031)
7 North America
7.1 North America Flu Vaccination Sales Quantity by Type (2020-2031)
7.2 North America Flu Vaccination Sales Quantity by Application (2020-2031)
7.3 North America Flu Vaccination 麻豆原创 Size by Country
7.3.1 North America Flu Vaccination Sales Quantity by Country (2020-2031)
7.3.2 North America Flu Vaccination Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Flu Vaccination Sales Quantity by Type (2020-2031)
8.2 Europe Flu Vaccination Sales Quantity by Application (2020-2031)
8.3 Europe Flu Vaccination 麻豆原创 Size by Country
8.3.1 Europe Flu Vaccination Sales Quantity by Country (2020-2031)
8.3.2 Europe Flu Vaccination Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Flu Vaccination Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Flu Vaccination Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Flu Vaccination 麻豆原创 Size by Region
9.3.1 Asia-Pacific Flu Vaccination Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Flu Vaccination Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Flu Vaccination Sales Quantity by Type (2020-2031)
10.2 South America Flu Vaccination Sales Quantity by Application (2020-2031)
10.3 South America Flu Vaccination 麻豆原创 Size by Country
10.3.1 South America Flu Vaccination Sales Quantity by Country (2020-2031)
10.3.2 South America Flu Vaccination Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Flu Vaccination Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Flu Vaccination Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Flu Vaccination 麻豆原创 Size by Country
11.3.1 Middle East & Africa Flu Vaccination Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Flu Vaccination Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Flu Vaccination 麻豆原创 Drivers
12.2 Flu Vaccination 麻豆原创 Restraints
12.3 Flu Vaccination Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Flu Vaccination and Key Manufacturers
13.2 Manufacturing Costs Percentage of Flu Vaccination
13.3 Flu Vaccination Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Flu Vaccination Typical Distributors
14.3 Flu Vaccination Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
听
听
*If Applicable.
